23 November 2023
AMOEBA : A year of field trials that confirms AXPERA’s strategic positioning
Amoéba announces the publication of its 2023 test results, a campaign year that allows the refining of AXPERA’s commercial strategy.
18 October 2023
AMOEBA : Publication of a new scientific paper in Plants
Amoéba announces the publication of a third peer-reviewed scientific article in Plants, presenting the efficacy of Amoéba’s biocontrol products on tomato late blight and powdery mildews of tomato.
16 October 2023
AMOEBA : Convincing results for the use of amoeba lysate in cosmetics.
Amoéba announces that it has obtained convincing results for the use of Willaertia magna C2c Maky lysate in cosmetic skin care and has filed a patent application for this invention.
12 October 2023
AMOEBA announces the beginning of construction of its USIBIAM biocontrol plant in Cavaillon
Amoéba announces the start of work on the USIBIAM industrial project in Cavaillon on schedule.
5 October 2023
Amoéba: first half-year reporting
Amoéba announces reporting its earnings for the first half of 2023
13 July 2023
Regulatory timetable for Europe’s biocontrol application on track
Amoéba confirms that the regulatory timetable for the biocontrol active substance application is in line with the Company’s forecasts.
5 June 2023
AMOEBA introduces its AXPERA brand for the biocontrol application
Amoéba announces today the brand name of its biocontrol solutions, with a view to commercialization expected in early 2025.
20 April 2023
Initiation of coverage by Portzamparc
Amoéba announces today that Portzamparc – BNP Paribas Group has initiated coverage on the company.
19 April 2023
Ordinary and extraordinary general meeting to be help on 25 May 2023
Amoéba informs that the notice of the meeting as a notice of convocation, including the agenda and the planned resolutions, was published in the BALO (Bulletin of obligatory legal announcements) of 19 april, 2023.
18 April 2023
AMOEBA : Availability of the 2022 Universal Registration Document
Amoéba announces that the 2022 Universal Registration Document was filed with the French Financial Markets Authority (Autorité des marchés financiers-AMF) on April 18, 2023
31 March 2023
Amoéba announces its collaboration with Nissan Chemical Corporation
Amoéba announces that Nissan Chemical Corporation has started a performance evaluation study of the mixture of one of its products with an Amoéba biocontrol experimental product.
30 March 2023
Amoéba : 2022 results
Amoéba today announces its annual results for the year ending 31 December 2022.
29 March 2023
Amoéba obtains €5.9 million in funding from BPI France as part of France 2030 program
Amoéba announces the support of BPI France in the framework of the national financing plan “France 2030”.
13 March 2023
Initiation report from the analyst Edison Group
Amoéba announces that Edison Group, a London-based equity research house, has initiated coverage on the company.
16 February 2023
Submission of the building permit application for the 100% biocontrol manufacturing unit
Amoéba announces that it has applied for building permit for its new production site dedicated to biocontrol application, based in Cavaillon in the south of France.
15 February 2023
Signature of a new financing agreement with Nice & Green
Amoéba announces the signature of a new simple bond financing agreement of 9 million euros with the Swiss company Nice & Green SA.
27 January 2023
Cancellation of the issue of the 8th optional tranche of OCAs and signature of a support contract with Redbridge Debt and Treasury Advisory
Amoéba announces that it has terminated its convertible bond issue contract with Nice & Green SA and waived the issue of the 8th optional tranche of 80 OCAs. In order to adapt its financial strategy to its new industrial transformation challenges, Amoéba has concluded a contract with Redbridge Debt and Treasury Advisory to assist it in its search for financing.
20 December 2022
US EPA approves Amoeba’s biocide in the US
Amoéba informs that the US Environmental Protection Agency (US EPA) has approved the use of the Willaertia magna C2c Maky as an active substance for use cooling systems.
14 December 2022
Issuance of the seventh tranche of 40 bonds convertible into shares
AMOEBA announces the issuance of the seventh tranche of 40 bonds convertible into shares as part of its new bond financing with incentive program with Nice & Green S.A.
3 November 2022
US EPA approves Amoeba’s biocontrol solution in the US
Amoéba announces that the US EPA has approved the use of the lysate of Willaertia magna C2c Maky as an active substance for use in plant protection.
20 October 2022
Publication of 2022 field trial results
Amoéba announces the publication of its 2022 field trial results, a record year for the number and performance of field trials.
19 October 2022
Amoeba withdraws its biocide file in Canada
Amoéba announces that it will not pursue the application for its living amoeba-based biocide in Canada.
18 October 2022
Publication of a new scientific article in Plants
Amoéba announces the publication of a scientific article concerning the efficacy of its biocontrol products to fight potato late blight.
12 October 2022
US EPA approves tolerance exemption for the biocontrol active substance on foodstuffs
Amoéba informs that the US EPA approves tolerance exemption for the biocontrol active substance on foodstuffs.
3 October 2022
2022 Interim Financial Report
Amoéba announces today that it has published its Interim Financial Report for 2022.
29 September 2022
Amoeba announces its half-year results for 2022
Amoeba announces its half-year results for 2022
29 September 2022
US EPA about to approve Amoeba’s biocontrol solution for use in agriculture
Amoéba informs that the United States Environmental Protection Agency (US EPA) has made a positive pre-decisional determination following its assessment of the application dossier for the use of the Lysate of Willaertia magna C2c Maky as a biocontrol active ingredient (biopesticide) in agriculture.
15 September 2022
AMOEBA : insuance of the sixth tranche of 60 bonds convertible into shares
Amoéba announces the issuance of the sixth tranche of 60 bonds convertible into shares.
10 August 2022
US EPA about to approve Amoéba’s biocide for use in closed cooling systems
Amoéba informs that the US EPA has made a positive pre-decisional determination for the use of Amoéba’s biocide in closed cooling systems.
13 June 2022
Amoéba : Issuance of the 5th tranche of OCA
Amoéba announces the issuance of the fifth tranche of 60 bonds convertible into shares as part of its new bond financing with incentive program with Nice & Green S.A.
30 May 2022
Amoéba: US regulatory calendar update
Amoeba announces that the US EPA, in charge of the evaluation of the biocide and biocontrol applications in the United States, has requested an extension of the assessment period : the conclusions should now be available in the second half of 2022.
6 May 2022
Ordinary and extraordinary general meeting to be held on 24 May 2022
Amoéba announces the availability of preparatory documents for the General Assembly of May 24, 2022
3 May 2022
Amoeba: Malta recommends the non-approval of the “biocide” active substance for the European territory
Amoeba announces that the Maltese authority recommends the non-approval of the biocidal active substance for the European territory
25 April 2022
Amoéba: Austria recommends the approval of the biocontrol application in Europe
Amoéba announces that AGES, in charge of the application for approval of the biocontrol active substance “Lysate of Willaertia magna C2c Maky”, recommends its approval for use in plant protection on the European territory.
13 April 2022
Amoéba : Publication of the 2021 Universal Registration Document
Amoéba announces that the 2021 Universal Registration Document was filed with the French Financial Markets Authority (Autorité des marchés financiers AMF) on April 12, 2022.
5 April 2022
Amoéba : Deferral of the 5th tranche of OCAs
Amoéba announces having exercised the suspension option relating to the issuance of the 5th tranche of OCAs, initially scheduled for April 5, 2022.
25 March 2022
Update of the European regulatory application calendar
Amoéba announces a report of the conclusion of the evaluation of the European biocide and biocontrol dossiers.
24 August 2021
Results of the 2nd cereal trial campaign
Amoeba confirms its biocontrol’s effectiveness against major cereal diseases
29 July 2021
Promising results of the Biocontrol-Grapewine application
Amoéba announces the results of the field trials 3rd campaign on grapes
5 July 2021
Postponement of the biocide active substance dossier
Malta commits to finalize the report in the 4th quarter of 2021
24 June 2021
Appointment of Philippe Dujardin to the Board of Directors
Philippe Dujardin replaces Pascal Reber as independent director
2 June 2021
General Meeting of June 24, 2021
Availability of the preparatory documents for the General meeting of 27 may 2021
27 May 2021
General Meeting second convocation
Due to a lack of quorum, the General Meeting is postponed to June 24, 2021
10 May 2021
General Assembly of May 27, 2021
Amoéba provides shareholders with preparatory documents
6 April 2021
Submission of the biocide application in the USA
Amoéba has submitted the application for approval of the biocidal active substance
6 April 2021
Massive new field trials campaign
Amoeba continues testing its biocontrol product in 2021
26 March 2021
Amoéba announces the 2020 financial year results
marked by the continued development of its biocidal and biocontrol applications
12 March 2021
Research partnership with the US group GOWAN COMPANY
Amoéba extends to the U.S.A. the testing of its biocontrol
10 March 2021
Appointment of Pierre Morgon to the Board of Directors
Amoéba has appointed Pierre Morgon as censor.
10 March 2021
Development and commercialization agreement
Signature of a Letter of Intent (LOI) with PHILAGRO France
18 December 2020
Signature of a non-exclusive development and marketing agreement
in Switzerland with Stähler for its vine Bioncontrol product.